Trial · NCT06807788
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Platelet Aggregation analyzed by optical aggregometry-ADP (AggRAM™- Helena Laboratories) | 14 days | Compare platelet aggregation analyzed by optical aggregometry-ADP (AggRAM™- Helena Laboratórios) between both groups |
| Secondary | Platelet aggregability by AggRAM™ arachidonic acid at baseline; | Baseline | Avaliation of Platelet aggregability by AggRAM™ arachidonic acid at baseline |
| Secondary | Platelet aggregability by AggRAM™ ADP after 14 days of use of Clopidogrel 75 mg/day; | 14 days | Evaluation of Platelet aggregability by AggRAM™ ADP after 14 days of use of Clopidogrel 75 mg/day; |
| Secondary | Platelet aggregability by Plateletworks-ADP at baseline and after 14 days of use of Clopidogrel 75 mg/day | 14 days | Evaluation of Platelet aggregability by Plateletworks-ADP at baseline and after 14 days of use of Clopidogrel 75 mg/day; |
| Secondary | Serum levels of ultrasensitive C-reactive protein (hs-CRP); | Baseline | Avaliation of Serum levels of ultrasensitive C-reactive protein (hs-CRP) |
| Secondary | Serum levels of immature platelets; | Baseline | Evaluation of Serum levels of immature platelets |
| Secondary | Platelet count | Baseline | Evaluation of Platelet count; |
| Secondary | Serum levels of P-Selectin | Baseline | Evaluation of Serum levels of P-Selectin |
| Secondary | Serum levels of interleukin 6 | Baseline | Evaluation of Serum levels of interleukin 6; |
| Secondary | Serum levels of Interleukin 1 | Baseline | Evaluation of interleukin 1 |
| Secondary | Serum levels of cholesterol ester transfer proteins; | Baseline | Evaluation of Serum levels of cholesterol ester transfer proteins; |
| Secondary | Serum levels of Lipoprotein(a) (LPa) | Baseline | Evaluation of Serum levels of Lipoprotein(a) (LPa) |
| Other | Subgroup Analysis- Sex | Baseline and 14 days | Sex (male/female) |
| Other | Subgroup Analysis- Age | Baseline and 14 days | Age (≥65 years or \< 65 years) |
| Other | Subgroup Analysis- BDI | Baseline and 14 days | Body Mass Index (\<30 or ≥ 30 kg/m2); |
| Other | Subgroup Analysis- Diabetes mellitus | Baseline and 14 days | Diabetes mellitus (presence or not); |
| Other | Subgroup Analysis- Use of Statins | Baseline and 14 days | Use of Statins (yes or no) |
| Other | Subgroup Analysis- Smoking | Baseline and 14 days | Current smoking (yes or no); |
| Other | Subgroup Analysis- Use of Nonsteroidal Anti-inflammatory drugs | Baseline and 14 days | Use of Nonesteroidal ANti-inflammatory drugs ( yes or no) |
| Other | Subgroup Analysis of Glomerular filtration rate (CKD-EPI) (< 60 mL/min/m2 or ≥ 60mL/min/m2) | Baseline and 14 days | CKD-EPI (\< 60 mL/min/m2 or ≥ 60mL/min/m2) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06807788/registered